PARATEK PHARMS
SpecialtyPARATEK PHARMS is a specialty pharmaceutical company focused on Infectious Disease, Dermatology. Key products include NUZYRA.
FDA Novel Drug Designations
(2018)See 1 novel approval →
PARATEK PHARMS at a Glance
- Fast trial execution (15 months median completion)
PARATEK PHARMS's Key Drugs
PARATEK PHARMS's core commercial portfolio centers on NUZYRA, XHANCE, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
PARATEK PHARMS's Recent FDA Approvals
New NDA/BLA approvals for PARATEK PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
PARATEK PHARMS's Therapeutic Areas
PARATEK PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PARATEK PHARMS's Top Competitors
PARATEK PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PARATEK PHARMS Pipeline Snapshot
Active clinical trials for PARATEK PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NUZYRA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/6 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges